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PURPOSE. The purpose of this study was to identify the molec-
ular basis of albinism in a large cohort of Italian patients
showing typical ocular landmarks of the disease and to provide
a full characterization of the clinical ophthalmic manifesta-
tions.
METHODS. DNA samples from 45 patients with ocular manifes-
tations of albinism were analyzed by direct sequencing analysis
of five genes responsible for albinism: TYR, P, TYRP1,
SLC45A2 (MATP), and OA1. All patients studied showed a
variable degree of skin and hair hypopigmentation. Eighteen
patients with distinct mutations in each gene associated with
OCA were evaluated by detailed ophthalmic analysis, optical
coherence tomography (OCT), and fundus autofluorescence.
RESULTS. Disease-causing mutations were identified in more
than 95% of analyzed patients with OCA (28/45 [62.2%] cases
with two or more mutations; 15/45 [33.3%] cases with one
mutation). Thirty-five different mutant alleles were identified of
which 15 were novel. Mutations in TYR were the most fre-
quent (73.3%), whereas mutations in P occurred more rarely
(13.3%) than previously reported. Novel mutations were also
identified in rare loci such as TYRP1 and MATP. Mutations in
the OA1 gene were not detected. Clinical assessment revealed
that patients with iris and macular pigmentation had signifi-
cantly higher visual acuity than did severe hypopigmented
phenotypes.
CONCLUSIONS. TYR gene mutations represent a relevant cause of
oculocutaneous albinism in Italy, whereas mutations in P pres-
ent a lower frequency than that found in other populations.
Clinical analysis revealed that the severity of the ocular mani-
festations depends on the degree of retinal pigmentation. (In-
vest Ophthalmol Vis Sci. 2011;52:1281–1289) DOI:10.1167/
iovs.10-6091
Albinism is a rare inherited disorder manifested by thecomplete or partial absence of pigment in the skin, hair, or
eyes due to a defect in melanin biosynthesis. It can be classified
as oculocutaneous albinism (OCA), when it involves the hair,
skin, and eyes, or ocular albinism (OA), when the phenotype is
mainly restricted to the eyes and the optic system and there-
fore is associated with specific ocular changes due to a reduced
amount of melanin in the developing eye.1,2 Classic OCA is
usually inherited as an autosomal recessive trait due to muta-
tions in four genes known as TYR,3 P (OCA2),4 TYRP1,5 and
SLC45A2 (MATP),6 which are responsible for OCA type 1
(OCA1, MIM 203100), type 2 (OCA2, MIM 203200), type 3
(OCA3, MIM 203290), and type 4 (OCA4, MIM 606574), re-
spectively. Two general forms of OA have been distinguished:
the X-linked recessive Nettleship-Falls form (OA1; MIM
300500) and autosomal recessive ocular albinism (AROA). OA1
results from mutations in the OA1 locus.7 AROA results from
mutations in TYR, P, and possibly TYRP1, thus representing a
phenotypically mild variant of OCA.8 OCA is a phenotypic
component of syndromic disorders due to different gene mu-
tations, including Hermansky-Pudlak (HPS, MIM 203300), Che-
diak-Higashi (CHS, MIM 214500), Griscelli (GS, MIM 214450;
607624; 609227), Tietz (TS, MIM 103500), ocular albinism
with sensorineural deafness (Waardenburg syndrome type II
with ocular albinism; WS2-OA, MIM 103470), Waardenburg
(WS, MIM 193500), Cross (oculocerebral syndrome with hy-
popigmentation, CS, MIM 257800), Prader Willi (PWS, MIM
176270), and Angelman (AS, MIM 105830) syndromes.
The eye and optic system abnormalities are common to all
types of albinism and are probably related to the reduction of
melanin during embryonic development and early postnatal
life.1 Characteristic changes in the optic system include re-
duced pigmentation of the iris (iris translucency) and of the
retinal pigment epithelium, foveal hypoplasia, decreased visual
acuity, misrouting of the optic fibers at the chiasm, nystagmus,
strabismus, and refractive errors.1The degree of skin and hair
From the 1Telethon Institute of Genetics and Medicine (TIGEM),
Naples, Italy; the 3Department of Ophthalmology, Seconda Universita’
degli Studi di Napoli, Naples, Italy; the 4Department of Ophthalmolog-
ical Science, Universita’ degli Studi di Napoli Federico II, Naples, Italy;
the 5Unit of Child Neurology and Psychiatry, IRCCS (Istituto Ricerca e
Cura a Carattere Scientifico) C. Mondino Institute of Neurology, Uni-
versita` di Pavia, Pavia, Italy; the 6Mother and Child Department, Uni-
versita’ degli Studi di Brescia, Brescia, Italy; the 7Department of Surgi-
cal Science and Transplantation, Universita’ degli Studi di Cagliari,
Cagliari, Italy; the 8Department of Pharmaceutical Sciences, Universita`
di Salerno, Fisciano, Italy; the 9Institute of Genetics and Biophysics
“Adriano Buzzati-Traverso” (IGB), CNR, Naples, Italy; and the 10Depart-
ment of Ophthalmology, Universita` degli Studi di Parma, Parma, Italy.
2These authors contributed equally to the work presented here
and should therefore be regarded as equivalent authors.
Supported by Telethon Grant TIGEM P21 and Grant
R01EY015136-01 from the National Eye Institute.
Submitted for publication June 21, 2010; revised August 11, 2010;
accepted August 11, 2010.
Disclosure: A. Gargiulo, None; F. Testa, None; S. Rossi, None; V.
Di Iorio, None; S. Fecarotta, None; T. de Berardinis, None; A.
Iovine, None; A. Magli, None; S. Signorini, None; E. Fazzi, None;
M.S. Galantuomo, None; M. Fossarello, None; S. Montefusco,
None; A. Ciccodicola, None; A. Neri, None; C. Macaluso, None; F.
Simonelli, None; E.M. Surace, None
*Each of the following is a corresponding author: Enrico Maria
Surace, Telethon Institute of Genetics and Medicine, via Pietro Cas-
tellino, 80131 Naples, Italy; surace@tigem.it.
Francesca Simonelli, Department of Ophthalmology, Seconda Uni-
versita’ degli Studi di Napoli, Naples, Italy; franctes@tin.it.
Genetics
Investigative Ophthalmology & Visual Science, March 2011, Vol. 52, No. 3
Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc. 1281
hypopigmentation, when present, varies along a wide clinical
spectrum of severe to mild phenotypes. The clinical spectrum
of OCA varies both within and among genotypes.
OCA1 is generally considered a severe form, due to the
absence of tyrosinase activity (OCA1A). Patients show a com-
plete lack of melanin production throughout life with light
blue to almost pink irises. Those with mutations determining a
decreased tyrosinase activity have a milder form (OCA1B) char-
acterized by blue to green/brown irises.3 OCA2, OCA3, and
OCA4 show some pigment accumulation over time in both
neural crest (skin, iris, and choroids melanocytes) and neuroec-
todermic (RPE cells) derived cells. OCA2, OCA3, and OCA4
patients typically have higher visual acuity than OCA1.9 OA
primarily affects the eye, sparing hair, or skin, as does AROA.
OA and AROA patients show the typical ocular landmarks of
albinism, with relatively normal skin and hair pigmentation.
Albinism can affect all ethnic backgrounds with an overall
prevalence of approximately 1 in 20,000 people.1 Prevalence
of the different forms of albinism varies considerably world-
wide. Several factors may be involved, including the dissimilar
prevalence of different founder gene mutations in different
populations.9
OCA2 is considered the most common type of OCA world-
wide, with the highest prevalence in Africans and African-
American OCA patients, which may, in part, result from the
existence of a single common deletion throughout many re-
gions of sub-Sahara Africa.1,10 Recent findings in a large series
of non-Hispanic Caucasian patients have shown, instead, that
OCA1 is the most frequent cause of OCA in Caucasian pa-
tients.11 OCA3 is virtually nonexistent in Caucasians, whereas
it affects frequently several African populations (1 in
8500).9,10 Mutations of MATP, responsible for OCA4, are ex-
tremely rare in Europeans (1 in 85,000), whereas they are
associated with the OCA phenotype in 24% of Japanese OCA
patients.9,12
At least 230 different pathologic gene mutations have been
reported in TYR, 84 in P, 17 in TYRP1, and 42 in SLC45A2 (cf.
Albinism Database; http://albinismdb.med.umn.edu/ devel-
oped by William Oetting and provided in the public domain by
the University of Minnesota, Minneapolis, MN). Common mu-
tations in different loci have been described in different pop-
ulations. However, the causative roles of some common DNA
variations are still controversial. In this respect, the p.R402Q
variation in the TYR locus (common among Caucasians and
African Americans), which results in a thermolabile tyrosinase
polypeptide with decreased catalytic activity at 37°C (the so-
called temperature-sensitive [TS] variant), has been considered
for years a nonpathologic polymorphism in different popula-
tions.13 Instead, different studies have indicated this variant as
a possible causative mutation, at least producing an additional
negative effect in combination with different heterozygous
mutations, even in nonallelic genes.14,15 In agreement with this
finding, the p.R402Q variation on one allele has recently been
identified in most Caucasian patients showing the AROA phe-
notype in combination with more severe TYRmutations on the
other allele.8 Moreover, the elevated frequency of this variant
in nondiagnostic OCA1 alleles in a large series of Caucasian
patients has suggested that this variant may contribute to the
OCA phenotype in some patients.11 In addition, previous stud-
ies reported a high frequency of multiple sequence variations
within a single individual.14 As a result of the high clinical and
genetic heterogeneity of OCA, it is difficult to clinically distin-
guish among the different forms of classic OCA.
Indeed, it appears that disease-causing mutations and clinical
manifestations correlate poorly. A relationship can be identified
only in the case of TYR gene mutations. TYR null mutations
producing inactive or incomplete polypeptides result in the most
severe OCA1A clinical phenotype, due to the lack of tyrosinase
enzyme function, which in turn blocks the first step of the mel-
anin biosynthetic pathway and, thus, the synthesis of melanin in
pigmented cells. TYR mutations producing a partially active or
hypomorphic tyrosinase enzymes result in the OCA1B milder
phenotype.1 Furthermore, genotype–phenotype correlations
are not clinically valuable in the case of P, TYRP1, and MATP
mutations. The lack of functional assays for the P, TYRP1, and
MATP proteins and the limited molecular genetic and clinical
data of both TYRP1 and MATP hamper the possibility for a
diagnostic and prognostic definition of these forms of albi-
nism.16 Finally, no genotype–phenotype correlations have
been identified in the case of mutations of OA1.17
Therefore, the side-by-side comparison of both molecular
and clinical characteristics of patients affected by distinct
genes and mutations may provide insights into the albinism
disease spectrum and also into a more accurate diagnosis and
genetic counseling.
In this study, we describe a comprehensive mutational
analysis of all genes associated with nonsyndromic albinism in
combination with a full clinical ophthalmic evaluation in a
large cohort of 45 Italian patients with a clinical diagnosis of
OCA.
MATERIALS AND METHODS
Patient Selection
The diagnostic inclusion criteria of patients were based on the pres-
ence of the following ophthalmic characteristic features: photophobia,
nystagmus, reduced visual acuity, strabismus, iris translucency, fundus
hypopigmentation, and foveal hypoplasia, possibly in combination
with various degrees of hypopigmentation of the skin and hair8; VEP
has not been considered necessary for the routine diagnosis of albi-
nism.18,19 Syndromic forms of albinism, such as Hermansky-Pudlak,
Chediak-Higashi, Griscelli, Tietz, ocular albinism with sensorineural
deafness, Waardenburg, Cross, Prader Willi, or Angelman syndromes
were excluded on clinical grounds, based on the absence of additional
clinical findings such as deafness; immune deficiency; hematologic
abnormalities or bleeding diathesis; heart, lung, genitourinary, gastro-
intestinal or central nervous system involvement; and the presence of
obesity and dysmorphic features, as reported at the time of the clinical
diagnosis from the ophthalmologist at the referring center.
All patients analyzed showed variable skin and hair involvement
with mild or severe degrees of hypopigmentation, representing the
clinical spectrum of OCA phenotypes.
Mutation Analyses
We analyzed genomic DNA of 45 Italian patients from 40 independent
families, referring to ophthalmic institutes in different Italian regions
and having a clinical diagnosis of nonsyndromic albinism. The research
adhered to the tenets of the Declaration of Helsinki. Informed consent
was obtained from each patient, or from the patient’s legal represen-
tatives in the case of children, after explanation of the nature and
possible consequences of the study. To establish a molecular diagnosis,
we performed direct DNA sequence analysis of five genes known to be
associated with albinism: TYR, P, TYRP1, MATP, and OA1. Patients
were initially screened for TYR and P mutations and, if negative, were
then screened for TYRP1, MATP, and OA1 gene mutations.
A detailed pedigree analysis of the extended families was per-
formed to determine the mode of inheritance, and in 22 independent
families, the segregation of mutations was confirmed by gene sequence
analysis in all family members.
Genomic DNA was extracted from patients’ peripheral whole
blood lymphocytes and, when available, from their parents, by using
standard techniques (Qiagen Italy, Milan, Italy). The complete coding
sequence and the exon–intron boundaries of the OA1, TYR, P, TYRP1,
and MATP genes were amplified by standard PCR (Taq Gold DNA
polymerase; Roche, Basel, Switzerland). Tyrosinase exon 1; OA1 exons
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1, 3, and 8; and MATP exon 3, were amplified as a pair of overlapping
fragments. The exon 1 of P and TYRP1 genes, which are noncoding,
was not analyzed. Human chromosome 11 contains a pseudogene,
known as the tyrosinase-like gene (TYRL, 11p11.2; MIM 191270), that
shares a 98.55% sequence identity with the 3-region of TYR (68 kb),
including exons 4 and 5. Thus, the identification of nucleotide variants
in TYR by PCR and DNA sequencing is a challenging task and could
generate false data due to the co-amplification from both loci. To allow
the direct and unequivocal identification of mutations, we used prim-
ers for a specific amplification of the TYR locus, as described in Chaki
et al.20
The PCR was performed in 35 cycles with 50 ng of genomic DNA
at 94°C for 1 minute, at the respective primer annealing temperature
for 1 minute, and at 72°C for 1 minute. The primers and reaction
conditions of the PCR amplification are available on request. Ampli-
cons were screened for mutations by direct sequencing (Prism Big Dye
terminator cycle sequencing V2.0 kit; Applied Biosystems, Inc. [ABI],
Foster City, CA), and the reactions were analyzed on a genetic analyzer
(Prism 3100; ABI). The sequenced exon and intron–exon boundaries
were compared against consensus sequences obtained from the Na-
tional Centre for Biotechnology Information Database (http://www.
ncbi.nlm.nih.gov/), using standard software for DNA sequencing anal-
ysis (Autoassembler, ver. 2.1; ABI).
Mutation nomenclature conformed to standard convention.21 The
identified nucleotide variations were researched in either the Albinism
Database (http://albinismdb.med.umn.edu/) or the Human Gene Mu-
tation Database (http://www.hgmd.cf.ac.uk/ac/index.php/ provided
in the public domain by the Institute of Medical Genetics, Cardiff,
Wales, UK) to check whether they are described as causative muta-
tions or polymorphisms.
Nine of 13 newly identified sequence variants leading to amino acid
missense substitution were tested in other affected and unaffected
family members, to verify the segregation with the albino phenotype.
Any novel missense variation was considered a possible causative
mutation if it was absent in at least 100 control chromosomes, analyzed
by denaturing high performance liquid chromatography (dHPLC). All
control products displaying a dHPLC pattern similar to the patient’s
were sequenced. The newly identified frameshift mutations were not
tested in control samples, and they were considered to be causative
mutations.
Phenotype Analysis
An additional full ophthalmic evaluation, including visual acuity mea-
surements, evaluation of ocular motility and iris translucency, biomi-
croscopic examination, fundus examination, fundus autofluorescence
(FAF), and retinography, was performed in 18 patients harboring
mutations of different genes causing albinism. A 4- and 3-point scale
according to Summers et al.22 was used to classify iris translucency and
macular transparency, respectively.
Autofluorescence was recorded with a standard confocal scanning
laser ophthalmoscope (Heidelberg Retina Angiograph II; Heidelberg
Engineering, Heidelberg, Germany). To amplify the autofluorescence
signal, we aligned the best five images obtained by using the integrated
system software and calculated a mean image.
Cross-sectional retinal reflectivity profiles were obtained with op-
tical coherence tomography (OCT3; Carl Zeiss Meditec, Inc.,
Oberkochen, Germany). Subjects underwent OCT imaging incorporat-
ing 512 A-scans over a 3-m transverse scanning length for an optimal
sampling rate of 400 A-scans per second centered on the fovea. Ac-
cording to the manufacturer, the longitudinal resolution of the present
model is 8 to 10 m, and the transverse resolution is approximately 20
m. The precise location and orientation of each scan were deter-
mined with the OCT simultaneous-view video images.
Because nearly all patients were affected by nystagmus, which
complicates the recording, OCT scans, and autofluorescence were
obtained in only 15 patients. Correlation analysis was performed with
Spearman’s test.
RESULTS
Mutational Analysis
We analyzed 45 Italian individuals showing ophthalmic char-
acteristic features of albinism including photophobia, nystag-
mus, reduced visual acuity, strabismus, iris translucency, fun-
dus hypopigmentation, and foveal hypoplasia possibly in
combination with various degrees of hypopigmentation of the
skin and hair (23 males, 22 females, mean age, 17.6 15 years)
from 40 independent families. We found causative DNA varia-
tion in 43 (95.6%) of 45 patients analyzed. We identified 2 or
more causative mutations in 62.2% of all patients, of which 8
(17.7%) were homozygotes and 20 (44.44%) were compound
heterozygotes. In 15 (33.3%) cases the second mutation was
not detected. We did not find mutations in the genes studied in
two (4.4%) patients (Fig. 1). In three patients, more than two
causative mutations were present, either in allelic (two cases)
or nonallelic (one case) genes (Table 1). Overall, we detected
35 different, and possibly causative, mutations in TYR, P,
TYRP1, and MATP, 15 (42.8%) of which were novel (Table 1).
Furthermore, we identified 20 DNA variations in TYR, P,
TYRP1, MATP, and OA1 that have been considered as poly-
morphisms (Supplementary Table S1, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.10-6091/-/DCSupplemental).
TYR was the most frequently mutated gene in our cohort of
patients (33/45; 73.3%), followed by P (6/45; 13.3%), MATP
(3/45; 6.7%), and TYRP1 (1/45; 2.3%). No causative mutations
were detected in the OA1 gene. A total of 22 missense, 6
nonsense, and 6 frameshift mutations and 1 splicing mutation
were identified. Four novel mutations in TYR and four in P
were detected. We also identified mutations in rare loci, in-
cluding six novel mutations in MATP and one in TYRP1 (Sup-
plementary Table S2, http://www.iovs.org/lookup/suppl/doi:
10.1167/iovs.10-6091/-/DCSupplemental).
OCA1 (TYR)
TYR mutational analysis showed 22 distinct mutations in 33
patients, including missense, frameshift, nonsense, and splic-
ing variations (Table 1). Thirteen of 23 missense mutations
identified were located in the exons 1 and 3.
The most frequent mutated allele identified was the
c.G1205A (p.R402Q variation), which was found in 17 patients
and 21 alleles. Because of the controversial causative role of
this mutation, we also analyzed the other OCA and OA genes in
four homozygous patients (P23–P26) and did not identify any
additional causative mutation in these distinct loci. Ten pa-
tients carrying the p.R402Q variation were compound
.
. .
.
.
FIGURE 1. Distribution of mutated genes involved in albinism based
on the results of mutational analysis in our cohort of patients.
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heterozygous in combination with either described or novel
causative mutant alleles. The p.R402Q variant was also found
in a patient bearing two causative mutations in MATP. In three
further patients (P30–P32) carrying the p.R402Q variation, a
second causative mutation was not detected.
We found three novel missense mutations: p.Y451C
(c.A1351G), p.C46Y (c.137CA), and p.H202Q (c.606TG),
all affecting amino acid residues highly conserved across evo-
lution (from Xenopus laevis to Homo sapiens). A fourth novel
mutation found in three compound heterozygous patients
leads to a frameshift (c.1177delG). In two patients (P3, P19)
we found three causative mutations in TYR.
OCA2 (P), OCA3 (TYRP1), and OCA4 (MATP)
Mutations of the P gene were found in six patients. All identi-
fied mutations (including four novel ones; Table 1) were mis-
sense variations. Two sibling patients (P37, P38) were homozy-
gous for the novel mutation c.2216TC (p.I739T) and one
patient (P35) was compound heterozygous for two known
mutations (c.1327GA, p.V443I and c.2360CT, p.A787V). In
the remaining three individuals, a second mutation was not
found (P34, P36, and P39).
The coding sequence of the TYRP1 gene was mutated in
only one patient (P40), showing a novel homozygous missense
mutation in exon 4 that results in a cysteine-to-tyrosine amino
acid change (p.C290Y, c.G869A). The absence of this variation
in 220 healthy control chromosomes with the absence of any
apparent mutations in the other OCA and OA genes, and also
the conservation of the amino acid residue across evolution,
suggests that this variation may cause the disease phenotype.
Finally, six different novel mutations were detected in
MATP gene in three patients. Patient 42 and 43 were com-
pound heterozygous for two novel missense MATP mutations.
Patient 41 showed two novel mutations affecting the first and
the seventh exons of MATP and an additional nonallelic TYR
gene variation (p.R402Q).
Identification of Polymorphisms
Direct sequencing analysis revealed 20 different polymor-
phisms in exons or into nearby intronic sequences of the
screened genes (Supplementary Table S1, http://www.iovs.
org/lookup/suppl/doi:10.1167/iovs.10-6091/-/DCSupplemental).
We found overall eight novel polymorphisms in P, TYRP1, and
MATP and none in the TYR gene.
Thirty percent of the exonic polymorphisms resulted in
amino acid changes, whereas the remaining ones were silent.
The P gene had a significantly high frequency of missense
variations with no apparent pathogenic significance (Supple-
mentary Table S1, http://www.iovs.org/lookup/suppl/doi:10.
1167/iovs.10-6091/-/DCSupplemental). Among them, we iden-
tified two novel nucleotide variations: c.1355TA (p.452V/E)
and c.1113CT (no change D371).
We found two new intronic polymorphisms of the TYRP1
gene with high frequency. IVS7–19InsA was identified in 36.9%
and IVS620C/T in 32.6% of the patients.
Patient 43 showed a c.1122GC and a c.G814A substitution
affecting exon 5 and 3, respectively, of the MATP gene that
lead to the nonpathogenic protein variations p.374F/L and
p.E272K.
Two polymorphic intronic variations were found at the
OA1 gene: IVS610G/C and IVS812T/C, both with a fre-
quency of 4.3%.
Phenotype Analysis
A detailed ophthalmic evaluation, including visual acuity mea-
surements, evaluation of ocular motility and iris translucency,
fundus examination, fundus autofluorescence (FAF), and opti-TA
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cal coherence tomography (OCT), was performed in 18 OCA
patients (mean age, 19  14 years) from 16 independent
families with mutations in each of the four OCA genes studied
(Table 2). Clinical analysis revealed that nystagmus and strabis-
mus were present in most patients independently from the
mutated gene. Autofluorescence showed absence of macular
pigment in 9 of 15 patients examined, even in those showing
an intermediate degree (grade 2) of fundus pigmentation (mac-
ular transparency evaluation).
The patients carrying P, TYRP1, and MATP mutations
showed a milder ocular phenotype than most patients carrying
TYR mutations. Those carrying TYR mutations showed high
prevalence of light blue (LB) iris pigmentation (11/12 cases)
and high degree of iris translucency (7/12 patients with grade
3 iris translucency). Fundus examination and autofluorescence
analysis revealed a high or intermediate degree of fundus hy-
popigmentation (9/12 patients with grade 1 or 2 macular
transparency), whereas OCT analysis demonstrated the ab-
sence of the foveal pit in 9 of 10 cases. Most patients (7/12)
displayed low visual acuity, ranging between 20/600 and 20/
200.
Three patients carrying P mutations showed gray (GG) or
gray-blue (GB) iris pigmentation with a variable amount of iris
pigment and punctate transillumination, a high degree of fun-
dus pigmentation (grade 3 in two of three patients), and the
presence of the foveal pit in two of three patients. In two
patients, visual acuity was preserved (from 20/60 to 20/40)
despite the presence of nystagmus and strabismus.
The only patient carrying mutations of TYRP1 showed a
mild ocular phenotype, LB iris, minimal punctuate transillumi-
nation, and presence of the foveal pit based on OCT evaluation
and a visual acuity of 20/100 in both eyes.
Two patients bearing MATP mutations presented heteroge-
neous clinical findings, with a more severe ocular involvement
and a worse visual acuity in the patient carrying the additional
p.R402Q variation (c.G1205A) of the TYR gene.
Correlation analysis revealed that, independent of the gene
mutation, reduced iris translucency and macular transparency
(as markers of pigmentation) were significantly associated with
(1) better visual acuity (P  0.0007); (2) the presence of
macular pigment assessed by autofluorescence analysis (P 
0.0001); (3) the presence of the foveal pit by OCT evaluation
(P  0.04); and (4) the absence of nystagmus (P  0.05).
Importantly, preserved visual acuity correlated with statistical
significance (P  0.0007) with presence of macular pigment,
as assessed by autofluorescence analysis. No correlation was
found between better visual acuity and the presence of the
foveal pit (P  0.3) or the absence of nystagmus (P  0.06).
Examples of clinical findings including fundus photography,
FAF, and OCT examinations in four patients with mutations in
four different OCA genes are reported in Figure 2. As shown in
the figure, a mild phenotype was found in two patients carry-
ing P and TYRP1 mutations, which showed presence of the
foveal pit, no visible choroidal macula vessels, and the pres-
ence of macular pigment evaluated by autofluorescence anal-
ysis. Two patients carrying TYR and MATP mutations, respec-
tively, showed absence of the foveal pit, visible choroidal
macula vessels, and absence of macular pigment by autofluo-
rescence analysis.
DISCUSSION
In this study, we provided the first comprehensive mutational
analysis of all genes associated with nonsyndromic albinism,
performed in combination with a detailed clinical ophthalmic
evaluation of a large series of Italian patients with albinism.
In agreement with previous results in Caucasian patients11
we found that the most frequent mutations are associated with
TYR in the Italian population rather than with P. We found
73.3% OCA1, 13.3% OCA2, 2.3% OCA3, and 6.7% OCA4 in 45
Italian patients. In 4.4% of the cases, we were not able to
identify any pathologic mutations. In 62.2% of patients we
found homozygous or compound heterozygous mutations,
whereas in 33.3% of cases we identified mutations in only one
allele.
We found a wide spectrum of causative mutations in TYR,
P, TYRP1, and MATP and additional DNA polymorphisms in
five genes associated with different forms of albinism. More-
over, we identified 15 novel causative mutations in four differ-
ent loci, expanding the database of OCA-causing mutations.
A missense mutation cluster was identified in putative func-
tional domains of the TYR enzyme.27,30 Consistently, our data
showed that many of the missense mutations identified are
located in/or alongside the copper-binding sites corresponding
to exons 1 and 3. Mutations in these regions are considered to act
either by affecting copper binding or by disrupting the substrate-
binding site.31 Our data confirm that different mutations within
the tyrosinase-coding region underlie OCA1 disorders of varying
severity. In one unusual subset of OCA1 patients, OCA1-TS, the
TABLE 2. Ophthalmic Features of 18 Patients Analyzed Phenotypically
Pt. Gene Age
Iris
Pigmentation
Iris
Translucens
Macular
Transparency
Foveal
Pit
Autofluorescence
Macular Pigment
CVA
RE
CVA
LE Nystagmus Strabismus
3 TYR 14 LB 3 1 No Absent 20/200 20/200 Yes No
4 TYR 12 LB 3 1 No Absent 20/100 20/100 Yes —
9 TYR 37 LB 2 2 No ND 20/200 20/200 Yes Yes
11 TYR 8 LB 2 2 — Absent 20/200 20/200 Yes Yes
15 TYR 16 LB 3 2 No Absent 20/600 20/600 Yes No
16 TYR 24 LB 3 2 No Absent 20/600 20/600 Yes No
17 TYR 9 LB 1 3 Yes ND 20/100 20/50 No Yes
18 TYR 13 GB 1 3 No Present 20/25 20/25 No No
22 TYR 15 LB 3 2 No Absent 20/100 20/100 Yes Yes
23 TYR 40 LB 3 1 No Absent 20/400 20/200 Yes Yes
26 TYR 12 LB 3 1 ND ND 20/400 20/400 Yes Yes
33 TYR 5 LB 2 3 No Present 20/100 20/100 No Yes
35 P 8 GB 2 2 Yes Absent 20/200 20/200 Yes Yes
37 P 41 GG 1 3 No Present 20/60 20/60 Yes Yes
38 P 34 GB 1 3 Yes Present 20/60 20/40 Yes Yes
40 TYRP1 18 LB 1 ND Yes Present 20/100 20/100 Yes Yes
41 MATP 51 GB 3 1 No Absent 20/400 20/200 Yes Yes
43 MATP 4 ND ND ND Yes Present 20/100 20/200 Yes Yes
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mutation generates a temperature-sensitive tyrosinase protein.32
Consequently, melanin synthesis occurs only in the cooler
areas of the body, such as the arms and legs. Several TS variants
of tyrosinase have been sequenced. One of these (p.R402Q)
represented the most common TYR mutation identified in our
cohort of Italian families (37% of patients), who showed an
evident OCA phenotype with various degrees of severity in
ocular phenotype. This finding is in agreement with recent
studies.8,14,15 The p.R402Q variation (c.G1205A) was identi-
fied in our cohort of patients, either in compound heterozy-
gotes (in combination with known or novel pathogenic mutant
alleles) or in patients who did not show a second causative
mutation. Interestingly, we also found this variation to be the
only identified mutation with a possible causative role in four
homozygous patients with an oculocutaneous phenotype, two
of whom showed severe visual loss. These data suggest a
causative role of the p.R402Q variation of TYR, which has been
considered for years a nonpathologic polymorphism.13 Fur-
thermore, we identified this variation as an additional nonal-
lelic mutation in 1 patient (P41) bearing two novel mutations
in MATP. This patient showed a more severe ocular involve-
ment in comparison with patients carrying only MATP muta-
tions, thus suggesting an additional negative effect of the
p.R402Q mutation in combination with allelic and nonallelic
mutations.
OCA2 is the most common type of albinism, especially in
black African OCA patients, occurring in approximately 50% of
OCA patients worldwide.33 We found mutations of P only in
14% of Italian patient, carrying either known or novel muta-
tions. Unlike from the TYR gene analysis, P gene mutations did
not appear to cluster in specific regions but they were found
between or in the proximity of transmembrane domain bor-
ders in the central region of the protein. Presently, few muta-
tions causing the OCA3 phenotype worldwide have been iden-
tified in the TYRP1 gene.5,34–36 TYRP1mutations causing OCA
have been considered virtually absent in Caucasians,11 al-
though a single German patient has been described.35 We
identified one patient carrying a novel homozygous missense
mutation of TYRP1 (p.C290Y), who showed a mild ocular
phenotype. This novel mutation affects an amino acid residue
that is highly conserved across evolution. Despite the low
frequency of mutations inMATP (OCA4) worldwide12 with the
exception of Japan, we found six novel MATP mutations in
three Italian patients with a variable OCA phenotype. As ex-
pected, based on the selection of patients who showed at least
some degree of skin and hair hypopigmentation, we did not
find any mutation of the OA1 gene.
We were unable to identify mutations in 4.4% of patients
screened, and we found mutations in only one allele in 33.3%
(15/45) of cases. In these patients, mutations may be present in
intronic or regulatory regions, which were not analyzed in our
molecular analysis. Also, large genomic rearrangements cannot
be identified with the strategy used in the present study.
Finally, in patients with unidentified mutations, the disease
may be due to mutations in OCA genes that are still to be
identified as OCA-causing genes.
In a previous study,14 we identified more than two caus-
ative mutations in three patients (P3, P20, P41), either in allelic
or nonallelic genes. Digenic mutation types (mutations in non-
allelic genes) have been described in some cases of ocular
FIGURE 2. Fundus photography, FAF,
and OCT analysis in four patients with
mutations in different OCA genes: P3 (A,
E, I), carrying TYR mutation; P36 (B, F,
J) bearing a P mutation; P40 (C, G, K)
with a TYRP1mutation; and P41 (D,H,
L) showing an MATP mutation (see Ta-
ble 1). (A–D) Fundus photographs: cho-
roidal vessels are visible in the macula in
P3 (A) and P41 (D), but they are not
visible in P36 (B) and P40 (C); (E–H)
FAF: please note the absence of macular
pigment in P3 (E) and P41 (H) and the
presence of macular pigment in P36 (F)
and P40 (G). (I–L) OCT of the posterior
pole crossing the fovea, showing ab-
sence of the foveal pit in P3 (I) and P41
(L) and presence of the foveal pit in
patients P36 (J) and P40 (K).
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albinism and Waardenburg syndrome.15,37 Our findings sup-
port the hypothesis that heterozygous mutations in nonallelic
genes may result in a more severe phenotype.
Our comprehensive analysis of clinical and molecular data
confirms that a phenotypic variability is present among pa-
tients and that it is generally independent from the mutated
gene and the specific mutation. The lack of a sufficient number
of patients with each gene mutation did not allow us to draw
genotype–phenotype correlations within and among geno-
types.
Most of the TYR patients showed a more severe ocular
phenotype than did patients bearing mutations of P, TYRP1, or
MATP, as previously reported in a genotype–phenotype corre-
lation study.28 However, independent of the gene involved, the
severity of the clinical phenotype inversely correlated with the
degree of retinal pigmentation, confirming previous find-
ings.38,39 In this respect, we found that visual acuity was
more preserved in patients with low iris translucency and
macular transparency assessed by autofluorescence analysis.
In addition, autofluorescence analysis showed absence of
macular pigment (and a poor visual acuity) also in those
patients in whom fundus pigmentation assessments revealed
an intermediate degree of macular transparency. These data
support the use of autofluorescence analysis as a more
sensitive analysis to predict the visual phenotype severity
compared with fundus macular transparency in albino pa-
tients. We also found that low visual acuity was not associ-
ated with the presence of the foveal pit, in accordance with
the recent report of Marmor et al.40
In conclusion, our clinical evaluation suggests that the de-
gree of ocular pigmentation correlates with preservation of
visual function. Our results confirm the wide clinical and ge-
netic heterogeneity of OCA. They also suggest that TYR muta-
tions cause a more severe ocular phenotype in most patients in
comparison with P, TYRP1, or MATP mutations. Data obtained
from the detailed ophthalmic evaluation also suggest that the
severity of ocular phenotype depends on the degree of retinal
pigmentation and support the use of autofluorescence analysis
of macular pigment as a sensitive prognostic tool to predict the
visual function in albino patients.
Finally, as the different OCA forms are indistinguishable on
clinical grounds, and also considering both the high frequency
of multiple DNA changes in the same patient and the lack of
clear cut correlations between the clinical phenotype and
molecular genotypes, we concluded that a comprehensive
mutational analysis of at least four genes, such as TYR, P,
MATP, and TYRP1 is necessary for the differential diagnosis
and genetic counseling of patients who have oculocutaneous
albinism. We believe that the wide range of patients analyzed
in the present study provides valuable information for a better
prognostic evaluation of patients with albinism and for a more
efficient identification of patients who could benefit from the
future experimental development of therapies.41,42
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